What is the 'patent cliff'?

Pharma-watchers throw around the term "patent cliff," and folks start running for cover. But what, precisely, is the drug industry afraid of? Thanks to a new forecast from IHS Global Insight, we can all apply numbers to our fears--at least to the ones that apply to 2009.

More than 100 pharma patents are set to expire by the end of this year alone. Many of those are not so newsworthy. But 13 of them are, and they include GlaxoSmithKline's herpes treatment Valtrex, bipolar remedy Lamictal, and migraine drug Imitrex; Johnson & Johnson's epilepsy/mood drug Topamax; Forest Laboratories' antidepressant Lexapro; and Roche's transplant drug CellCept.

Overall, however, there are two companies most likely to be hard-hit by this year's cliff, Global Insight concludes: GlaxoSmithKline and Pfizer. Novartis and Takeda are close behind. But there's one caveat--one ray of hope-filled sunshine--the consultancy believes that just a few of the drugs falling off that cliff this year have enough market potential for generic drugmakers to pursue them in a big way. We're not sure how they arrived at that conclusion, but they're the experts.

- check out PharmaGossip's post
- read the PharmaTimes story


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.